Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population

Van de Wyngaert Z, Carpentier B,Pascal L, Lionne-Huyghe P, Leduc I, Srour M,Vasseur M, Demarquette H,Terriou L,Herbaux C,Manier S, Bossard Jb,Barbieux S, Chauvet P,Willaume A,Nudel M, Bories C,Gibier Jb, Facon T, Boyle Em

BRITISH JOURNAL OF HAEMATOLOGY(2020)

引用 27|浏览2
暂无评分
关键词
AL-Amyloidosis,daratumumab,frailty
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要